U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C6H5O7.4K.Mg
Molecular Weight 558.8976
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of POTASSIUM MAGNESIUM CITRATE (4:1:2)

SMILES

[Mg++].[K+].[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

InChI

InChIKey=ZBBBMBVEBOYSBA-UHFFFAOYSA-H
InChI=1S/2C6H8O7.4K.Mg/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;;/q;;4*+1;+2/p-6

HIDE SMILES / InChI

Molecular Formula K
Molecular Weight 39.0983
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Mg
Molecular Weight 24.305
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H5O7
Molecular Weight 189.0997
Charge -3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Potassium magnesium citrate has being proven to be an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. Liquid potassium magnesium citrate has being studied in clinical trial for controlling Hypertension. Provision of alkali as potassium-magnesium citrate is an effective countermeasure for the increased risk of renal stone disease associated with immobilization. Despite an increase in urine calcium concentration, the relative saturation of calcium oxalate decreased due to citrate chelation of calcium and the concentration of undissociated uric acid decreased due to the significant increase in urine pH. Potassium magnesium citrate is a nutritional supplement that fights kidney stones in three different ways. The potassium provided by the supplement raises the pH of the urine, making it more alkaline, thus reducing the amount of calcium that the urine can dissolve. When there is less calcium in the urine, fewer calcium kidney stones can form. The magnesium in the supplement reduces the amount of calcium the kidneys pump out of the body and into the urine. And the citrate in the supplement keeps oxalates dissolved in the urine so they are flushed away before they can form kidney stones.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q99798
Gene ID: 50.0
Gene Symbol: ACO2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Preventing
K-MAG

Approved Use

K-MAG is indicated in all states of deficiency of potassium and magnesium, which generally occur with a feeling of tiredness, muscle weakness and cramps.

Launch Date

1988
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Effects of Potassium Magnesium Citrate Supplementation on 24-Hour Ambulatory Blood Pressure and Oxidative Stress Marker in Prehypertensive and Hypertensive Subjects.
2016 Sep 15
Patents

Sample Use Guides

Syrup potassium magnesium citrate 20Meq per dose three times a day for 12 weeks
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:54:02 GMT 2023
Edited
by admin
on Fri Dec 15 15:54:02 GMT 2023
Record UNII
TRI2520XBJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
POTASSIUM MAGNESIUM CITRATE (4:1:2)
Systematic Name English
RELYTE
Brand Name English
Potassium magnesium citrate [WHO-DD]
Common Name English
MAGNESIUM POTASSIUM CITRATE (1:4:2)
Systematic Name English
KMGCIT
Common Name English
1,2,3-PROPANETRICARBOXYLIC ACID, 2-HYDROXY-, MAGNESIUM POTASSIUM SALT (2:1:4)
Common Name English
HCACTIVE
Brand Name English
K-MAG
Brand Name English
POTASSIUM-MAGNESIUM CITRATE (4:1:2)
Systematic Name English
Code System Code Type Description
CAS
8030-84-0
Created by admin on Fri Dec 15 15:54:02 GMT 2023 , Edited by admin on Fri Dec 15 15:54:02 GMT 2023
NON-SPECIFIC STOICHIOMETRY
MESH
C066902
Created by admin on Fri Dec 15 15:54:02 GMT 2023 , Edited by admin on Fri Dec 15 15:54:02 GMT 2023
PRIMARY
FDA UNII
TRI2520XBJ
Created by admin on Fri Dec 15 15:54:02 GMT 2023 , Edited by admin on Fri Dec 15 15:54:02 GMT 2023
PRIMARY
PUBCHEM
10437763
Created by admin on Fri Dec 15 15:54:02 GMT 2023 , Edited by admin on Fri Dec 15 15:54:02 GMT 2023
PRIMARY
EPA CompTox
DTXSID80929846
Created by admin on Fri Dec 15 15:54:02 GMT 2023 , Edited by admin on Fri Dec 15 15:54:02 GMT 2023
PRIMARY
CAS
137590-34-2
Created by admin on Fri Dec 15 15:54:02 GMT 2023 , Edited by admin on Fri Dec 15 15:54:02 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE